BF Biosciences Launches Zeptide in Pakistan to Target Diabetes and Obesity

BF Biosciences Limited has announced the commercial launch of Zeptide® (Tirzepatide), a next-generation therapy for Type 2 diabetes and obesity, now available in Pakistan in a user-friendly, pre-filled syringe. The company, a trailblazer in Pakistan’s biopharmaceutical sector, disclosed the development in a notice to the Pakistan Stock Exchange (PSX) earlier today. Zeptide® contains Tirzepatide, a synthetic polypeptide recently approved by the US Food and Drug Administration (FDA). The drug acts as a dual agonist for GLP-1 and GIP receptors, representing a breakthrough in both blood sugar management and weight reduction. Manufactured at BF Biosciences’ advanced facility built on European technology, the new pre-filled syringe format is designed to maximize dosing accuracy and patient safety, while minimizing the risk of errors and improving adherence. “With Zeptide®, we are proud to bring a world-class therapeutic option to Pakistani patients,” a company spokesperson said. This innovation reinforces our commitment to developing essential, locally manufactured biologics that meet international quality standards.” To ensure global-level validation, Zeptide® underwent rigorous quality, structural, and potency testing at a leading biological mass spectrometry lab in the United States, as well as at a national university in Pakistan. The launch of Zeptide® is a direct result of BF Biosciences’ IPO proceeds utilization plan, underlining the company’s strategy of reinvesting in Pakistan’s healthcare infrastructure. Pakistan faces one of the world’s highest rates of diabetes, with over 9 million people undiagnosed. Obesity is also rampant, with 57% of women and 41% of men classified as overweight or obese, factors that increase the risk of developing Type 2 diabetes by up to seven times. BF Biosciences is already a market leader in GLP-1 generics, with its Sematide brand of semaglutide being the most prescribed in the country. As Pakistan’s first biopharmaceutical plant, the company has spent over a decade producing essential medicines for conditions ranging from hepatitis C and cancer to cardiology, diabetes, and nephrology. The company expressed confidence that Zeptide® will not only drive its own growth but also further its mission to address critical, unmet patient needs in Pakistan